⌘K
t
AstraZeneca PLC announced on 9 November 2023 that Philip Broadley, its senior independent Non-Executive Director, has been appointed as Non-Executive Director and Chair designate to the Board of Lancashire Holdings Limited. This appointment is effective from 8 November 2023.
| Date | 9 Nov 2023 |
| Time | 15:00:00 |
| Category | Miscellaneous |
| ID | 9490S |
9 November 2023 15:00 BST
Director Declaration
AstraZeneca PLC (the Company) today announced that Philip Broadley, senior independent Non-Executive Director of the Company, has been appointed as Non-Executive Director and Chair designate to the Board of Lancashire Holdings Limited with effect from 8 November 2023.
This announcement is made pursuant to Listing Rule 9.6.14 R (2).
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC